Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
Business Wire (Wed, 1-Jul 8:00 AM ET)
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Business Wire (Thu, 28-May 8:00 AM ET)
Market Chameleon (Tue, 27-Jan 4:52 AM ET)
Market Chameleon (Mon, 8-Dec 3:22 AM ET)
Vyome’s AI Acquisition Signals Strategic Shift Toward Digital Inflammation Therapies
Market Chameleon (Mon, 29-Sep 3:38 AM ET)
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Vyome Holdings trades on the NASDAQ stock market under the symbol HIND.
As of August 24, 2026, HIND stock price climbed to $2.30 with 2,073 million shares trading.
HIND has a beta of 1.52, meaning it tends to be more sensitive to market movements. HIND has a correlation of 0.04 to the broad based SPY ETF.
HIND has a market cap of $16.14 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that HIND belongs to (by Net Assets): VXF.
HIND has underperformed the market in the last year with a return of -79.0%, while SPY returned +21.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HIND shares. However, HIND has outperformed the market in the last 3 month and 2 week periods, returning +3.1% and +6.5%, while SPY returned +3.1% and -1.2%, respectively. This indicates HIND has been having a stronger performance recently.
HIND support price is $2.13 and resistance is $2.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIND shares will trade within this expected range on the day.